BACKGROUND: The authors demonstrated previously that the combination of topotecan (TPT) and carboplatin (CBP) was more effective than current chemotherapeutic combinations used to treat retinoblastoma in an orthotopic xenograft model. However, systemic coadministration of these agents is not ideal, because both agents cause dose-limiting myelosuppression in children. METHODS: To overcome the toxicity associated with systemic TPT and CBP, the authors explored subconjunctival delivery of TPT or CBP in an orthotopic xenograft model and in a genetic mouse model of retinoblastoma (Chx10-Cre;Rb(lox/lox);p107(-/-);p53(lox/lox)). The effects of combined subconjunctival CBP (CBP(subcon)) and systemic TPT (TPT(syst)) were compared with the effects of combined TPT(subcon) and CBP(syst.) at clinically relevant dosages. RESULTS: Pharmacokinetic and tumor-response studies, including analyses of ocular and hematopoietic toxicity, revealed that CBP(subcon)/TPT(syst) was more effective and had fewer side effects than TPT(subcon)/CBP(syst). CONCLUSIONS: For the first time, retinoblastoma was ablated and long-term vision was preserved in a mouse model by using a clinically relevant chemotherapy regimen. These results eventually may be translated into a clinical trial for children with this debilitating cancer.
BACKGROUND: The authors demonstrated previously that the combination of topotecan (TPT) and carboplatin (CBP) was more effective than current chemotherapeutic combinations used to treat retinoblastoma in an orthotopic xenograft model. However, systemic coadministration of these agents is not ideal, because both agents cause dose-limiting myelosuppression in children. METHODS: To overcome the toxicity associated with systemic TPT and CBP, the authors explored subconjunctival delivery of TPT or CBP in an orthotopic xenograft model and in a genetic mouse model of retinoblastoma (Chx10-Cre;Rb(lox/lox);p107(-/-);p53(lox/lox)). The effects of combined subconjunctival CBP (CBP(subcon)) and systemic TPT (TPT(syst)) were compared with the effects of combined TPT(subcon) and CBP(syst.) at clinically relevant dosages. RESULTS: Pharmacokinetic and tumor-response studies, including analyses of ocular and hematopoietic toxicity, revealed that CBP(subcon)/TPT(syst) was more effective and had fewer side effects than TPT(subcon)/CBP(syst). CONCLUSIONS: For the first time, retinoblastoma was ablated and long-term vision was preserved in a mouse model by using a clinically relevant chemotherapy regimen. These results eventually may be translated into a clinical trial for children with this debilitating cancer.
Authors: J Thompson; E O George; C A Poquette; P J Cheshire; L B Richmond; S S de Graaf; M Ma; C F Stewart; P J Houghton Journal: Clin Cancer Res Date: 1999-11 Impact factor: 12.531
Authors: Nikia A Laurie; Jonathan K Gray; Jiakun Zhang; Mark Leggas; Mary Relling; Merrill Egorin; Clinton Stewart; Michael A Dyer Journal: Clin Cancer Res Date: 2005-10-15 Impact factor: 12.531
Authors: Uma H Athale; Clinton Stewart; John F Kuttesch; Albert Moghrabi; William Meyer; Charles Pratt; Amar Gajjar; Richard L Heideman Journal: J Clin Oncol Date: 2002-01-01 Impact factor: 44.544
Authors: Nikia A Laurie; Stacy L Donovan; Chie-Schin Shih; Jiakun Zhang; Nicholas Mills; Christine Fuller; Amina Teunisse; Suzanne Lam; Yolande Ramos; Adithi Mohan; Dianna Johnson; Matthew Wilson; Carlos Rodriguez-Galindo; Micaela Quarto; Sarah Francoz; Susan M Mendrysa; R Kiplin Guy; Jean-Christophe Marine; Aart G Jochemsen; Michael A Dyer Journal: Nature Date: 2006-11-02 Impact factor: 49.962
Authors: Guillermo L Chantada; Adriana C Fandino; Angel M Carcaboso; Eduardo Lagomarsino; Maria T G de Davila; Myriam R Guitter; Adriana B Rose; Julio Manzitti; Guillermo F Bramuglia; David H Abramson Journal: Invest Ophthalmol Vis Sci Date: 2008-10-31 Impact factor: 4.799
Authors: Chie-Schin Shih; Nikia Laurie; Jeremy Holzmacher; Yunyu Spence; Amit C Nathwani; Andrew M Davidoff; Michael A Dyer Journal: Neuromolecular Med Date: 2009-03-22 Impact factor: 3.843
Authors: Rachel C Brennan; Sara Federico; Cori Bradley; Jiakun Zhang; Jacqueline Flores-Otero; Matthew Wilson; Clinton Stewart; Fangyi Zhu; Kip Guy; Michael A Dyer Journal: Cancer Res Date: 2011-04-22 Impact factor: 12.701
Authors: Ching-Hon Pui; Amar J Gajjar; Javier R Kane; Ibrahim A Qaddoumi; Alberto S Pappo Journal: Nat Rev Clin Oncol Date: 2011-06-28 Impact factor: 66.675
Authors: Rachel C Brennan; Ibrahim Qaddoumi; Shenghua Mao; Jianrong Wu; Catherine A Billups; Clinton F Stewart; Mary Ellen Hoehn; Carlos Rodriguez-Galindo; Matthew W Wilson Journal: J Clin Oncol Date: 2016-10-31 Impact factor: 44.544
Authors: Michael W Bishop; Jessica M Somerville; Armita Bahrami; Sue C Kaste; Rodrigo B Interiano; Jianrong Wu; Shenghua Mao; Frederick A Boop; Regan F Williams; Alberto S Pappo; Sandeep Samant Journal: Sarcoma Date: 2015-06-03